Research Article

PRPF3-Associated Autosomal Dominant Retinitis Pigmentosa and CYP4V2-Associated Bietti’s Crystalline Corneoretinal Dystrophy Coexist in a Multigenerational Chinese Family

Xiaohong Meng,1,2 Qiyou Li,1,2 Hong Guo,3 Haiwei Xu,1,2 Shiyong Li,1,2 and Zhengqin Yin1,2

1Southwest Hospital and Southwest Eye Hospital, Third Military Medical University, Chongqing 400038, China
2Key Lab of Visual Damage and Regeneration & Restoration of Chongqing, Chongqing 400038, China
3Department of Medical Genetics, Third Military Medical University, Chongqing 400038, China

Correspondence should be addressed to Shiyong Li; shiying_li@126.com and Zhengqin Yin; qinzyin@aliyun.com

Received 16 May 2017; Accepted 2 July 2017; Published 7 August 2017

Academic Editor: Mineo Kondo

Copyright © 2017 Xiaohong Meng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To characterize the clinical and molecular genetic characteristics of a large, multigenerational Chinese family showing different phenotypes. Methods. A pedigree consisted of 56 individuals in 5 generations was recruited. Comprehensive ophthalmic examinations were performed in 16 family members affected. Mutation screening of CYP4V2 was performed by Sanger sequencing. Next-generation sequencing (NGS) was performed to capture and sequence all exons of 47 known retinal dystrophy-associated genes in two affected family members who had no mutations in CYP4V2. The detected variants in NGS were validated by Sanger sequencing in the family members. Results. Two compound heterozygous CYP4V2 mutations (c.802-8_810del17insGC and c.992A>C) were detected in the proband who presented typical clinical features of BCD. One missense mutation (c.1482C>T, p.T494M) in the PRPF3 gene was detected in 9 out of 22 affected family members who manifested classical clinical features of RP. Conclusions. Our results showed that two compound heterozygous CYP4V2 mutations caused BCD, and one missense mutation in PRPF3 was responsible for adRP in this large family. This study suggests that accurate phenotypic diagnosis, molecular diagnosis, and genetic counseling are necessary for patients with hereditary retinal degeneration in some large multigenerational family.

1. Introduction

Retinitis pigmentosa (RP) (MIM 268000) is the most common form of hereditary retinal degeneration (HRD), with a worldwide prevalence of 1 in 4000 [1]. The disease can be inherited in an autosomal recessive (AR), autosomal dominant (AD), or X-linked manner [2]. Autosomal dominant RP (adRP) is the most common form of RP and typically begins with night blindness in the early teens, followed by progressive loss in the peripheral visual field, subsequent loss of vision, and eventually legal blindness. To date, mutations in 22 genes have been associated with adRP (RetNet: http://www.sph.uth.tmc.edu/retnet/sum-dis.htm, last updated November 16, 2016), of which five genes have been reported in Chinese adRP patients [3–7].

Bietti’s crystalline corneoretinal dystrophy (BCD) (MIM 210370) is an autosomal recessive retinal dystrophy that is characterized by numerous tiny glistening yellow-white crystals that are scattered at the posterior pole of the retina, progressive atrophy of the retinal pigment epithelium (RPE), and choroidal sclerosis. Patients with BCD are usually present in the 2nd or 3rd decade of life and progress to legal blindness by the 5th or 6th decade [8]. Mutations in the CYP4V2 gene (MIM 608614) are associated with BCD [9]. BCD is relatively common in the East Asian populations, especially in Chinese and Japanese populations [9–18].
2. Methods

2.1. Pedigree. A pedigree consisted of 56 individuals in 5 generations was recruited. The Ethics Review Board of the Southwest Hospital (Chongqing, China) approved the research protocol (number 2012-11), which adhered to the tenets of the Declaration of Helsinki, and informed consent was obtained from all participants.

The proband (Figure 1, VI:1) was initially presented to our medical institution for genetic counseling based on the observation that most of the family members developed night blindness and visual loss and even complete blindness, resulting in an inability to work. This five-generation family from Southwest China was assessed in terms of RP and BCD. Thirty-nine participants were ascertained at the Southwest Eye Hospital, Southwest Hospital, Chongqing, China (Figure 1). No consanguineous marriage in the family was declared.

The proband presented clinical features that were compatible with a diagnosis of BCD (VI:1), and the family members were subsequently evaluated. Twenty-two living individuals in the family had the clinical features of RP and presented similar symptoms of night blindness and progressive reduction in their field of vision. The RP phenotype followed an autosomal dominant pattern of inheritance in this pedigree (Figure 1).

Thirteen affected individuals (III:9, IV:1, IV:3, IV:4, IV:5, IV:6, IV:10, IV:12, IV:14, IV:20, V:3, V:9, V:12, and VI:1) and twenty-six unaffected family members (Table 1) underwent examination, including best-corrected visual acuity testing with the Snellen vision chart, fundoscopy, slit-lamp biomicroscopy, spectral domain optical coherence tomography (SD-OCT, Spectralis OCT, Version 6.0; Heidelberg Engineering, Germany), full-field electroretinogram (FERG), and multifocal electroretinogram (mfERG). For the ages 6 months, 1, 2, 3, and 4 years old, the visual acuity was assessed using Teller acuity cards and then converted into Snellen vision chart.

2.2. Mutation Screening. Genomic DNA was extracted from peripheral blood samples of 39 family members (Table 1) using a QIAamp DNA Blood Midi Kit (Qiagen, Hilden, Germany) following the manufacturer’s standard procedure. All coding exons and intron-exon boundaries of the CYP4V2 gene were amplified by polymerase chain reaction (PCR) using primers described by Li et al. [9]. The PCR products were subsequently purified with a TIANgen Mini Purification Kit (Tiangen Biotech Co. Ltd., Shanghai, China) and sequenced by Sanger sequencing with an ABI BigDye Terminator Cycle Sequencing Kit v3.1 (Applied Biosystems (ABI), Foster City, CA). CYP4V2 sequencing was performed in eight patients (III:9, IV:1, IV:6, IV:12, V:1, V:12, VI:1, and VI:2), and the detected mutation was further screened in 12 affected family members and 11 unaffected members.

Next-generation sequencing (NGS) was then applied to two affected family members with RP (III:9 and IV:1), who did not have CYP4V2 mutations, then to identify disease-causing variants in 47 RP-related genes including the PRP31, CRB1, PRPF8, CA4, TULP1, PRPF3, ABCA4, RP665, EYS, CERKL, NRL, FAM161A, FSCN2, TOPORS, SNRNP200, SEMA4A, PRCD, NR2E3, MERTK, UH2A, PDE6B, PROM1, KLHL7, PDE6A, RGR, CNGB1, IDH3B, SAG, GUC1A1, CNGB1, BEST1, TTC8, C2orf71, ARL6, IMPG2, PDE6G, ZNF513, DHDDS, PRP6, CLRN1, MAK, CDHR1, FLVCR1, RLBP1, SPATA7, AIP1, and LRAT genes. The detected variants in NGS were validated by Sanger
| Number | Gender | Age | First symptom | Phenotype | BCVA OD | BCVA OS | Eye complications | Systemic diseases | PRPF3 mutation | CYP4V2 mutations |
|--------|--------|-----|---------------|-----------|---------|---------|------------------|------------------|----------------|-----------------|
| III:8  | Female | 76  | None          | Normal    | 20/250  | 20/250  | Cataract         | ND               | ND             | ND              |
| III:9  | Male   | 80  | Night blindness | RP        | LP      | LP      | Cataract         | ND               | MT             | ND              |
| III:10 | Female | 80  | None          | Normal    | 20/50   | 20/50   | Cataract         | ND               | ND             | ND              |
| IV:1   | Female | 82  | Night blindness | RP        | LP      | LP      | Cataract         | MT               | ND             | ND              |
| IV:3   | Male   | 57  | Night blindness | RP        | LP      | LP      | Cataract         | ND               | MT             | ND              |
| IV:5   | Male   | 57  | Night blindness | RP        | LP      | LP      | Cataract         | ND               | ND             | ND              |
| IV:6   | Male   | 57  | Night blindness | RP        | LP      | LP      | Cataract         | MT               | Wild            | Wild            |
| IV:7   | Female | 54  | None          | Normal    | 20/30   | 20/30   | None             | Wild             | Wild            | Wild            |
| IV:10  | Male   | 39  | Night blindness | RP        | 20/200  | 20/200  | None             | MT               | Wild            | Wild            |
| IV:12  | Male   | 35  | Night blindness | RP        | 20/400  | LP      | None             | ND               | Wild            | Wild            |
| IV:14  | Male   | 55  | Night blindness | RP        | 20/100  | 20/200  | Cataract         | MT               | Wild            | Wild            |
| IV:15  | Female | 50  | None          | Normal    | 20/35   | 20/35   | None             | ND               | ND             | ND              |
| IV:16  | Female | 51  | None          | Normal    | 20/35   | 20/20   | None             | ND               | ND             | ND              |
| IV:18  | Male   | 49  | None          | Normal    | 20/40   | 20/40   | None             | ND               | ND             | ND              |
| IV:20  | Male   | 45  | Night blindness | RP        | 20/100  | 20/200  | None             | MT               | Wild            | Wild            |
| V:1    | Female | 57  | None          | Normal    | 20/20   | 20/25   | None             | Breast cancer    | ND             | MT              |
| V:2    | Male   | 60  | None          | Normal    | 20/30   | 20/30   | Cataract         | Fatty liver disease | ND         | Wild            |
| V:3    | Female | 55  | Night blindness | RP        | 20/10   | 20/200  | None             | Breast cancer    | MT             | Wild            |
| V:7    | Male   | 45  | None          | Normal    | 20/30   | 20/30   | Myopia           | Wild             | Wild            | Wild            |
| V:8    | Female | 46  | None          | Normal    | 20/18   | 20/18   | None             | Wild             | Wild            | Wild            |
| V:9    | Male   | 43  | Night blindness | RP        | 20/200  | LP      | Myopia           | MT               | Wild            | Wild            |
| V:11   | Male   | 24  | None          | Normal    | 20/18   | 20/18   | None             | Wild             | Wild            | Wild            |
| V:12   | Male   | 22  | Night blindness | RP        | 20/100  | 20/100  | Myopia           | MT               | Wild            | Wild            |
| V:13   | Male   | 13  | None          | Normal    | 20/30   | 20/20   | None             | ND               | Wild            | Wild            |
| V:15   | Female | 8   | None          | Normal    | 20/20   | 20/20   | None             | ND               | Wild            | Wild            |
| V:17   | Male   | 37  | None          | Normal    | 20/25   | 20/25   | None             | ND               | Wild            | Wild            |
| V:18   | Female | 35  | None          | Normal    | 20/18   | 20/18   | High myopia      | ND               | ND             | ND              |
| V:19   | Female | 35  | None          | Normal    | 20/25   | 20/20   | Myopia           | ND               | ND             | ND              |
| V:20   | Male   | 33  | None          | Normal    | 20/18   | 20/18   | None             | Wild             | Wild            | Wild            |
| V:31   | Male   | 15  | None          | Normal    | 20/18   | 20/18   | Myopia           | ND               | ND             | ND              |
| VI:1   | Male   | 33  | Decreased vision | BCD      | 20/25   | 20/30   | Myopia, uveitis  | Wild             | MT             | MT              |
| VI:12  | Female | 29  | None          | Normal    | 20/40   | 20/50   | High myopia      | ND               | ND             | ND              |
| VI:10  | Female | 22  | None          | Normal    | 20/18   | 20/18   | Myopia           | ND               | Wild            | Wild            |
| VI:12  | Male   | 15  | None          | Normal    | 20/20   | 20/20   | None             | ND               | Wild            | Wild            |
| Number | Gender | Age | First symptom | Phenotype | BCVA OD | OS | Eye complications | Systemic diseases | PRPF3 mutation     | CYP4V2 mutations   |
|--------|--------|-----|---------------|-----------|---------|----|------------------|------------------|-------------------|--------------------|
| VI:14  | Male   | 13  | None          | Normal    | 20/20   | 20/20 | None             | None             | ND                | Wild               |
| VI:15  | Male   | 10  | None          | Normal    | 20/20   | 20/20 | None             | None             | ND                | Wild               |
| VI:16  | Male   | 9   | None          | Normal    | 20/20   | 20/20 | None             | None             | ND                | Wild               |
| VII:1  | Male   | 5   | None          | Normal    | 20/30   | 20/30 | None             | None             | ND                | MT                 |
| VII:2  | Female | 1   | None          | Normal    | 20/30   | 20/200| Hyperopia        | None             | ND                | Wild               |

MT: mutation; ND: not detected; LP: light perception; NLP: nonlight perception.
sequencing and screened in other 6 affected and 7 unaffected individuals in the family.

3. Results

3.1. Clinical Features. The demographic and clinical features of the living affected members and mutation carriers are summarized in Table 1. The age of enrollment ranged from 1 to 82 years. The visual acuity ranged from 20/30 to nonlight perception (NLP). Seven family members had refractive errors, including myopia (ranging −0.75 to −8 diopters) and astigmatism, and twelve members presented with cataract. All affected individuals except for the proband had congenital night blindness, and seven affected members already presented legal blindness. The proband’s mother (V:1) and aunt (V:3) had breast cancer, and his father (V:2) had fatty liver disease.

3.2. Mutations in the CYP4V2 Gene. Two previously reported CYP4V2 mutations (c.802-8_810del17insGC and c.992A>C (p.H331P)) were detected in this family. The proband (VI:1) was compound heterozygous for both mutations. The c.802-8_810del17insGC mutation was maternally derived (V:1), whereas the c.992A>C mutation was paternally inherited (V:2). Two other family members (V:9 and VII:1) were heterozygous for the c.802-8_810del17insGC mutation.
Figure 3: Continued.
3.3. Mutations in the PRPF3 Gene. Targeted NGS of two affected members (IV:1 and III:9) revealed one common missense mutation in the PRPF3 gene (c.1481C>T) (Figure 2), which was then screened by Sanger sequencing in 8 affected (III:9, IV:1, IV:3, IV:6, IV:14, V:9, V:12, and VI:1) and seven unaffected family members (IV:9, V:1, V:7, V:11, V:16, V:20, and VI:13) for cosegregation analysis.

3.4. Clinical and Molecular Manifestations of Affected Family Members. Two types of clinical and molecular manifestations were observed in this family: (i) a BCD phenotype that was related to the compound heterozygous CYP4V2 mutations and (ii) a RP phenotype that was associated with the PRPF3 mutation and followed an autosomal dominant pattern of inheritance.

3.4.1. Type 1 (Proband VI:1). The proband was a 33-year-old man referred to us for genetic counseling based on a significant decrease in visual acuity starting at the age of 17 years. The patient developed night blindness in his early 30s. He had high myopia (−7.00 D) in both eyes, and best-corrected Snellen visual acuity was 20/30 in his both eyes. There was a history of chronic uveitis in his left eye since age 28. He was diagnosed with BCD based on clinical findings that included numerous tiny glistening yellow-white crystals scattered at the posterior pole of the retina, RPE atrophy (Figure 3), and decreased responses in FERGs and mfERGs.

Two previously reported disease-causing mutations in CYP4V2 (c.802-8_810del17insGC in exon 7 and c.992A>C, p.H331P) were identified in the proband [19]. The compound heterozygosity was confirmed by screening his unaffected parents; his mother (V:1) carried the c.802-8_810del17insGC variant, and his father (V:2) harbored the c.992A>C mutation. The proband’s unaffected son (VII:1) had the c.802-8_810del17insGC mutation, whereas no pathogenic CYP4V2 mutations were detected in the apparently normal daughter (VII:2). Notably, no PRPF3 mutations were detected in the proband.

3.4.2. Type 2. In addition to the proband, other family members affected with adRP presented with night blindness since birth. Best-corrected visual acuity was from 200/400 to NLP. Fundus examination showed severe features of RP, with a mass of bone-spicule pigmentation depositions, more severe RPE atrophy involving the macular and choroidal sclerosis extending to the midperipheral retina, whereas partial attenuation of the retinal blood vessels, slight waxy pallor of the optic disc, was presented (Figure 4). FERG demonstrated undetectable responses both in scotopic and photopic conditions and extinguished mfERG.

One PRPF3 mutation, c.1481C>T (p.T494M), was detected in 13 family members, including 11 males and 2 females. No novel mutation and previously reported mutations were detected in the other 45 genes in the panel. The identified mutation (c.1481C>T) cosegregated with the RP phenotype in 11 affected family members tested and was not observed in 9 unaffected family members (Figure 1). This mutation was observed across four generations. Taken together, the c.1481C>T mutation was considered to be the main cause of adRP in this family.

4. Discussion

PRPF3 (MIM 607301) is a precursor mRNA-processing factor gene that was first identified for adRP in 2002 [20]. In the present study, a pathogenic mutation (c.1481C>T, p.T494M) in the PRPF3 gene was identified in 11 individuals presenting an adRP phenotype in a five-generation Chinese family. The molecular genetic features of a Chinese pedigree with a PRPF3 mutation have been previously
reported. The c.1481C>T mutation is considered to be one of the most common mutations in PRPF3 [20–25]. Previous reports have shown that patients harboring the c.1481C>T mutation develop early-onset night blindness, visual field loss, and visual acuity loss between the ages of 30 and 40, as well as loss of ERG responses after the age of 30. Compared to those in previously reported Japanese, Spanish, Korean, Swiss, and North American families, members of this Chinese family with the c.1481C>T mutation presented a more severe disease phenotype, which included congenital blindness, severe visual acuity loss, extended RPE atrophy, and completely extinguished ERG responses.

Mutations in the CYP4V2 gene (MIM 608614) are the only known causative factor for BCD to date. The CYP4V2 gene consists of 11 exons and encodes a 525 amino acid protein belonging to the CYP450 family. CYP4V2 is widely expressed in tissues, including the retina, RPE, lymphocytes, heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas, which has been thought to play a crucial role in fatty acid and corticosteroid metabolism. In the present study, two compound heterozygous mutations in CYP4V2 (c.802-8_810del17insGC and c.992A>C) were identified in the proband who presented typical BCD. In our previous study, CYP4V2 mutation screening among 92 Chinese patients with BCD showed that c.802-8_810del17insGC and c.992A>C are common pathogenic mutations in Chinese with BCD [26]. The parents of the proband are not a consanguineous marriage couple. So we speculate that these heterozygous mutations in Chinese population may be universal. This phenomenon may be related to the common ancestor based on the huge population of China. The heterozygous state of the same gene carried by parents is consistent with the autosomal recessive inheritance pattern. This will be important for prenatal testing for family planning, early finding carrier status, and determining risk of inheritance in Chinese.

Coexistence of variants in two or three genes associated with retinal degeneration has rarely been reported in a family [3]. In the present study, we identified the coexistence of two distinct phenotypes in one family, namely, BCD and RP,
which were caused by the pathogenic variants in the CYP4V2 and PRPF3 genes, respectively. The mode of inheritance of the two diseases was maintained in this family, in which BCD demonstrated an autosomal recessive trait and RP showed an autosomal dominant trait.

Two types of clinical and molecular manifestations identified in this study include (i) a BCD phenotype related to CYP4V2 mutations and (ii) an RP phenotype related to PRPF3 variants. Clinical features for (i) BCD and (ii) RP of mutations and (ii) an RP phenotype related to the two diseases was maintained in this family, in which the genotype is independent. Our study provides an insight into the clinical effects of two independent gene mutations in a large family to facilitate accurate diagnosis and disease counseling.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors are grateful to Chen Sun, Mingfang Zhang, Gang Wang, and Min Wang for their great support. This work was supported by the National Basic Research Program of China (973 Program, 2013CB967002 and 2013CB967003) and the National Natural Science Foundation of China (81200710).
[21] V. Vaclavik, M. C. Gaillard, L. Tiab, D. F. Schorderet, and F. L. Munier, "Variable phenotypic expressivity in a Swiss family with autosomal dominant retinitis pigmentosa due to a T494M mutation in the PRPF3 gene," *Molecular Vision*, vol. 16, pp. 467–475, 2010.

[22] Y. Wada, T. Itabashi, H. Sato, and M. Tamai, "Clinical features of a Japanese family with autosomal dominant retinitis pigmentosa associated with a Thr494Met mutation in the HPRP3 gene," *Graefe’s Archive for Clinical and Experimental Ophthalmology*, vol. 242, no. 11, pp. 956–961, 2004.

[23] C. Kim, K. J. Kim, J. Bok et al., "Microarray-based mutation detection and phenotypic characterization in Korean patients with retinitis pigmentosa," *Molecular Vision*, vol. 18, pp. 2398–2410, 2012.

[24] M. Martinez-Gimeno, M. J. Gamundi, I. Hernan et al., "Mutations in the pre-mRNA splicing-factor genes PRPF3, PRPF8, and PRPF31 in Spanish families with autosomal dominant retinitis pigmentosa," *Investigative Ophthalmology & Visual Science*, vol. 44, no. 5, pp. 2171–2177, 2003.

[25] F. Blanco-Kelly, M. Garcia-Hoyos, M. Cortón et al., "Genotyping microarray: mutation screening in Spanish families with autosomal dominant retinitis pigmentosa," *Molecular Vision*, vol. 18, pp. 1478–1483, 2012.

[26] X. H. Meng, H. Guo, H. W. Xu et al., "Identification of novel CYP4V2 gene mutations in 92 Chinese families with Bietti’s crystalline corneoretinal dystrophy," *Molecular Vision*, vol. 20, pp. 1806–1814, 2014.